Hobart Private Capital’s GSK GSK Stock Holding History

Hobart Private Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,787	Closed	-$366K	–	152
2020 Q3	$366K	Sell	7,787 -9,437	-55%	-$473K	0.19%	109
2020 Q2	$878K	Sell	17,224 -8,619	-33%	-$442K	0.49%	47
2020 Q1	$1.22M	Sell	25,843 -3,764	-13%	-$201K	0.84%	31
2019 Q4	$1.74M	Buy	29,607 +1,585	+6%	+$88.2K	1.06%	27
2019 Q3	$1.49M	Buy	28,022 +125	+0.4%	+$6.43K	1.02%	26
2019 Q2	$1.4M	Sell	27,897 -1,533	-5%	-$76.9K	0.97%	27
2019 Q1	$1.54M	Sell	29,430 -3,688	-11%	-$184K	1.17%	23
2018 Q4	$1.58M	Buy	33,118 +3,796	+13%	+$187K	1.36%	21
2018 Q3	$1.47M	Buy	29,322 +3,646	+14%	+$185K	1.13%	27
2018 Q2	$1.29M	Sell	25,676 -1,795	-7%	-$90.4K	1.05%	31
2018 Q1	$1.34M	Buy	27,471 +915	+3%	+$42.6K	1.18%	25
2017 Q4	$1.18M	Buy	+26,556	New	+$1.23M	1.05%	31

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Hobart Private Capital's GSK Position: Q4 2020 in Review

Hobart Private Capital sold out of GSK (GSK) in Q4 2020, closing a stake of 7,787 shares — an estimated $366K sold.

Hobart Private Capital first reported a position in GSK in Q4 2017 and held it in 12 quarters. The position peaked at $1.74M in Q4 2019. 819 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Hobart Private Capital reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Hobart Private Capital sold 7,787 GSK shares in Q4 2020, an estimated $366K.
Hobart Private Capital first reported a position in GSK in Q4 2017 and held it in 12 quarters.
Hobart Private Capital's GSK position peaked at $1.74M in Q4 2019.
819 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Hobart Private Capital's 13F filing for Q4 2020, filed 11 Mar 2024.